A genome-wide study of lipid response to fenofibrate in Caucasians: A combined analysis of the GOLDN and ACCORD studies

Pharmacogenetics and Genomics

Volumn 26, Issue 7, 2016, Pages 324-333

  Irvin, Marguerite R ^a   Rotroff, Daniel M ^b   Aslibekyan, Stella ^a   Zhi, Degui ^a   Hidalgo, Bertha ^a   Motsinger Reif, Alison ^b   Marvel, Skylar ^b   Srinivasasainagendra, Vinodh ^a   Claas, Steven A ^a   Buse, John B ^c   Straka, Robert J ^d   Ordovas, Jose M ^e   Borecki, Ingrid B ^f   Guo, Xiuqing ^g   Chen, Ida Y D ^g   Rotter, Jerome I ^g   Wagner, Michael J ^c   Arnett, Donna K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e TUFTS UNIVERSITY   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

cholesterol; dyslipidemia; fenofibrate; genome wide association study; lipid; lipoprotein; triglyceride

Indexed keywords

FENOFIBRATE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; GENETIC MARKER;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CHROMOSOME 19; CLINICAL TRIAL (TOPIC); FEMALE; GENE LOCUS; GENETIC MARKER; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HISPANIC; HOMEOBOX; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MALE; META ANALYSIS; MIDDLE AGED; PRIORITY JOURNAL; TREATMENT RESPONSE; BLOOD; DRUG EFFECTS; GENETICS; LIPID METABOLISM; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT;

CLINICAL TRIALS AS TOPIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FENOFIBRATE; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPIDS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84961393542     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000219     Document Type: Article

References (46)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
2. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol 1998; 14 (Suppl B): 14B-17B.
3. Pejic RN, Lee DT. Hypertriglyceridemia. J Am Board Fam Med 2006; 19: 310-316.
4. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371: 32-41.
5. Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014; 371: 22-31.
6. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384: 626-635.
7. Khetarpal SA, Rader DJ. Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics. Arterioscler Thromb Vasc Biol 2015; 35: e3-e9.
8. Baye TM, Tiwari HK, Allison DB, Go RC. Database mining for selection of SNP markers useful in admixture mapping. BioData Min 2009; 2: 1.
9. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171: 1-13.
10. Steiner G. Fibrates and coronary risk reduction. Atherosclerosis 2005; 182: 199-207.
11. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 2004; 6: 148-157.
12. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16: 763-772.
13. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-Aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
14. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
15. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-Term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) randomised controlled trial. Lancet 2005; 366: 1849-1861.
16. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
17. Wierzbicki AS. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Curr Opin Lipidol 2010; 21: 352-358.
18. Barter PJ, Rye KA. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?. Circulation 2006; 113: 1553-1555.
19. Aslibekyan S, Goodarzi MO, Frazier-Wood AC, Yan X, Irvin MR, Kim E, et al. Variants identified in a GWAS meta-Analysis for blood lipids are associated with the lipid response to fenofibrate. PLoS ONE 2012; 7: e48663.
20. Irvin MR, Zhang Q, Kabagambe EK, Perry RT, Straka RJ, Tiwari HK, et al. Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study. Pharmacogenet Genomics 2012; 22: 367-372.
21. Wojczynski MK, Gao G, Borecki I, Hopkins PN, Parnell L, Lai CQ, et al. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. J Lipid Res 2010; 51: 3316-3323.
22. Shen J, Arnett DK, Parnell LD, Peacock JM, Lai CQ, Hixson JE, et al. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes Care 2008; 31: 910-915.
23. Smith JA, Arnett DK, Kelly RJ, Ordovas JM, Sun YV, Hopkins PN, et al. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur J Hum Genet 2008; 16: 603-613.
24. Irvin MR, Kabagambe EK, Tiwari HK, Parnell LD, Straka RJ, Tsai M, et al. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ Cardiovasc Genet 2010; 3: 462-467.
25. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99 (12A): 21i-33i.
26. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
27. Liu Y, Ordovas JM, Gao G, Province M, Straka RJ, Tsai MY, et al. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. J Hum Genet 2008; 53: 709-717.
28. Aslibekyan S, Kabagambe EK, Irvin MR, Straka RJ, Borecki IB, Tiwari HK, et al. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenet Genomics 2012; 22: 191-197.
29. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955-959.
30. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. Bioinformatics 2010; 26: 2867-2873.
31. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods 2012; 9: 179-181.
32. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods 2013; 10: 5-6.
33. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529.
34. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
35. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45: 1274-1283.
36. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States; 2014. Atlanta: GA. Department of Health and Human Services
37. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008; 40: 189-197.
38. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41: 56-65.
39. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, et al. Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population. PLoS One 2012; 7: e51954.
40. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40: 161-169.
41. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, Ripatti S, et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol 2010; 30: 2264-2276.
42. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009; 41: 47-55.
43. Holmen OL, Zhang H, Fan Y, Hovelson DH, Schmidt EM, Zhou W, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014; 46: 345-351.
44. Vrablik M, Hubacek JA, Dlouha D, Lanska V, Rynekrova J, Zlatohlavek L, et al. Impact of variants within seven candidate genes on statin treatment efficacy. Physiol Res 2012; 61: 609-617.
45. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
46. Moffatt P, Thomas GP. Osteocrin - beyond just another bone protein?. Cell Mol Life Sci 2009; 66: 1135-1139.